Literature DB >> 30360731

Kinase Targets for Mycolic Acid Biosynthesis in Mycobacterium tuberculosis.

Shahinda S R Alsayed1, Chau C Beh2,3, Neil R Foster2, Alan D Payne4, Yu Yu1, Hendra Gunosewoyo1.   

Abstract

BACKGROUND: Mycolic acids (MAs) are the characteristic, integral building blocks for the mycomembrane belonging to the insidious bacterial pathogen Mycobacterium tuberculosis (M.tb). These C60-C90 long α-alkyl-β-hydroxylated fatty acids provide protection to the tubercle bacilli against the outside threats, thus allowing its survival, virulence and resistance to the current antibacterial agents. In the post-genomic era, progress has been made towards understanding the crucial enzymatic machineries involved in the biosynthesis of MAs in M.tb. However, gaps still remain in the exact role of the phosphorylation and dephosphorylation of regulatory mechanisms within these systems. To date, a total of 11 serine-threonine protein kinases (STPKs) are found in M.tb. Most enzymes implicated in the MAs synthesis were found to be phosphorylated in vitro and/or in vivo. For instance, phosphorylation of KasA, KasB, mtFabH, InhA, MabA, and FadD32 downregulated their enzymatic activity, while phosphorylation of VirS increased its enzymatic activity. These observations suggest that the kinases and phosphatases system could play a role in M.tb adaptive responses and survival mechanisms in the human host. As the mycobacterial STPKs do not share a high sequence homology to the human's, there have been some early drug discovery efforts towards developing potent and selective inhibitors.
OBJECTIVE: Recent updates to the kinases and phosphatases involved in the regulation of MAs biosynthesis will be presented in this mini-review, including their known small molecule inhibitors.
CONCLUSION: Mycobacterial kinases and phosphatases involved in the MAs regulation may serve as a useful avenue for antitubercular therapy. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Mycobacterium; formulations; kinase; mycolic acids; phosphatase; small molecule inhibitors; tuberculosis.

Mesh:

Substances:

Year:  2019        PMID: 30360731     DOI: 10.2174/1874467211666181025141114

Source DB:  PubMed          Journal:  Curr Mol Pharmacol        ISSN: 1874-4672            Impact factor:   3.339


  7 in total

1.  MtrP, a putative methyltransferase in Corynebacteria, is required for optimal membrane transport of trehalose mycolates.

Authors:  Arek K Rainczuk; Stephan Klatt; Yoshiki Yamaryo-Botté; Rajini Brammananth; Malcolm J McConville; Ross L Coppel; Paul K Crellin
Journal:  J Biol Chem       Date:  2020-03-26       Impact factor: 5.157

2.  Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.

Authors:  Shahinda S R Alsayed; Shichun Lun; Alan Payne; William R Bishai; Hendra Gunosewoyo
Journal:  Bioorg Chem       Date:  2020-11-19       Impact factor: 5.275

3.  Facile synthesis and antimycobacterial activity of isoniazid, pyrazinamide and ciprofloxacin derivatives.

Authors:  Shahinda S R Alsayed; Shichun Lun; Alan Payne; William R Bishai; Hendra Gunosewoyo
Journal:  Chem Biol Drug Des       Date:  2021-03-16       Impact factor: 2.873

4.  Design, synthesis, and biological evaluation of novel arylcarboxamide derivatives as anti-tubercular agents.

Authors:  Shahinda S R Alsayed; Shichun Lun; Giuseppe Luna; Chau Chun Beh; Alan D Payne; Neil Foster; William R Bishai; Hendra Gunosewoyo
Journal:  RSC Adv       Date:  2020-02-19       Impact factor: 4.036

5.  Adjuvant activity of Mycobacteria-derived mycolic acids.

Authors:  Mio Kubota; Ei'ichi Iizasa; Yasushi Chuuma; Hideyasu Kiyohara; Hiromitsu Hara; Hiroki Yoshida
Journal:  Heliyon       Date:  2020-05-27

6.  In Silico Drug Repurposing Approach: Investigation of Mycobacterium tuberculosis FadD32 Targeted by FDA-Approved Drugs.

Authors:  Nolwazi Thobeka Portia Ngidi; Kgothatso Eugene Machaba; Ndumiso Nhlakanipho Mhlongo
Journal:  Molecules       Date:  2022-01-20       Impact factor: 4.411

7.  Design, synthesis and evaluation of novel indole-2-carboxamides for growth inhibition of Mycobacterium tuberculosis and paediatric brain tumour cells.

Authors:  Shahinda S R Alsayed; Shichun Lun; Anders W Bailey; Amreena Suri; Chiang-Ching Huang; Mauro Mocerino; Alan Payne; Simone Treiger Sredni; William R Bishai; Hendra Gunosewoyo
Journal:  RSC Adv       Date:  2021-04-26       Impact factor: 3.361

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.